Oncomine Solutions for Solid Tumor Clinical Research

Rely on NGS for solid tumor genomic profiling

The number of molecular biomarkers relevant for precision oncology research is rapidly growing across solid tumors, and in many cases sequential single-gene testing methods do not yield desired results in time or for only a limited number of biomarkers. Therefore, next-generation sequencing (NGS) has become a technology of choice in precision oncology research for genomic profiling from formalin-fixed paraffin-embedded (FFPE) tissue or liquid biopsy samples*.


Oncomine solutions for FFPE tissue testing

Choose from targeted to comprehensive solid tumor ngs solutions.

 

Oncomine assays cover biomarkers across multiple solid tumors and enable labs to choose the most efficient tool for each tumor sample. 

Multi-cancer

Oncomine Precision Assay​

50 genes​
DNA & RNA inputs​
SNVs/indels​
CNVs​
Fusions

Multi-cancer

Oncomine Pan-Cancer Cell-Free Assay​

52 genes​
DNA & RNA inputs​
SNVs/nndels​
Full-length APC, FBXW7, ​
PTEN,TP53​
CNVs​
Fusions

Lung

Oncomine Lung cfTNA Assay

12 genes​
DNA & RNA inputs​
SNVs/indels​
CNVs​
Fusions

Breast

Oncomine Breast cfDNA Assay v2

12 genes​
SNVs/indels​
CNVs​
TP53

Colon

Oncomine Colon cfDNA Assay​

14 genes​
SNVs/indels

Explore Oncomine solutions for liquid biopsy sample testing

A diverse menu of targeted assays with multi-cancer and tumor type-specific coverage to fit your clinical research needs.


Oncomine solutions for emerging biomarker testing

Cancer research is increasingly focused on precision oncology approaches that rely on the detection of biomarkers.

 

Deeper knowledge of molecular pathways, their interactions, and fundamental understanding of cancer biology may elucidate the progression and help predict the response of future treatments.

 

Oncomine solutions provide highly automated end-to-end workflows that enable oncology biomarker detection in a broad spectrum of laboratories.


Ready to speak with a Thermo Fisher representative?

Want to learn more?  We are happy to answer any questions you have about Oncomine Reporter.

 

For Research Use Only. Not for use in diagnostic procedures.

*Scott JA, et al. Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data. JCO Oncol Pract. 2024 Jan;20(1):145-153.

Case Number: 61467